In our study of 869 pediatric AML patients, we showed an independent favorable outcome for the patients with NPM1 mutations in terms of 5-year EFS (P = 0.001) and OS (P = 0.016) compared to the patients with NPM1 wild-type. This evidence concerns the gene NPM1 and acute myeloid leukemia.